Have a feature idea you'd love to see implemented?
Let us know!
GPCR Structure Therapeutics Inc
Price (delayed)
$30.1
Market cap
$1.72B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.19
Enterprise value
$1.55B
We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Our differentiated
Highlights
GPCR's EPS has soared by 60% YoY
GPCR's quick ratio has surged by 168% year-on-year but it is down by 33% since the previous quarter
GPCR's debt is up by 14% YoY but it is down by 6% QoQ
The net income has contracted by 44% YoY and by 10% from the previous quarter
The equity has declined by 2.6% since the previous quarter
Key stats
What are the main financial stats of GPCR
Market
Valuations
Earnings
Shares outstanding
57.2M
Market cap
$1.72B
Enterprise value
$1.55B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$110.69M
EBITDA
-$108.58M
Free cash flow
-$104.33M
Per share
Balance sheet
Liquidity
EPS
-$2.19
Free cash flow per share
-$1.83
Book value per share
$15.69
Revenue per share
$0
TBVPS
$16.33
Total assets
$933.22M
Total liabilities
$36.42M
Debt
$4.39M
Equity
$896.8M
Working capital
$890.22M
Debt to equity
0
Current ratio
27.63
Quick ratio
27.38
Net debt/EBITDA
1.54
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-15.7%
Return on equity
-16.4%
Return on invested capital
-22.7%
Return on capital employed
-12.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GPCR stock price
How has the Structure Therapeutics stock price performed over time
Intraday
-7.98%
1 week
-20.14%
1 month
-22.46%
1 year
-41.36%
YTD
-26.15%
QTD
-31.42%
Financial performance
How have Structure Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.16M
Net income
-$110.55M
Gross margin
N/A
Net margin
N/A
GPCR's operating income has plunged by 68% YoY and by 16% from the previous quarter
The net income has contracted by 44% YoY and by 10% from the previous quarter
Growth
What is Structure Therapeutics's growth rate over time
Valuation
What is Structure Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GPCR's EPS has soared by 60% YoY
GPCR's P/B is 44% less than its last 4 quarters average of 3.4
The equity has declined by 2.6% since the previous quarter
Efficiency
How efficient is Structure Therapeutics business performance
GPCR's return on equity has surged by 72% year-on-year and by 18% since the previous quarter
GPCR's ROIC has soared by 64% YoY and by 23% from the previous quarter
The ROA has soared by 60% year-on-year and by 18% since the previous quarter
Dividends
What is GPCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GPCR.
Financial health
How did Structure Therapeutics financials performed over time
GPCR's quick ratio has surged by 168% year-on-year but it is down by 33% since the previous quarter
The current ratio has soared by 164% YoY but it has contracted by 33% from the previous quarter
GPCR's debt is 100% lower than its equity
The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
GPCR's debt is up by 14% YoY but it is down by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.